These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21185752)

  • 1. Pharmacogenomics of warfarin dose requirements in Hispanics.
    Cavallari LH; Momary KM; Patel SR; Shapiro NL; Nutescu E; Viana MA
    Blood Cells Mol Dis; 2011 Feb; 46(2):147-50. PubMed ID: 21185752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
    Linder MW; Bon Homme M; Reynolds KK; Gage BF; Eby C; Silvestrov N; Valdes R
    Clin Chem; 2009 Oct; 55(10):1861-8. PubMed ID: 19679631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.
    Botton MR; Bandinelli E; Rohde LE; Amon LC; Hutz MH
    Br J Clin Pharmacol; 2011 Sep; 72(3):442-50. PubMed ID: 21320153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
    Takahashi H; Wilkinson GR; Nutescu EA; Morita T; Ritchie MD; Scordo MG; Pengo V; Barban M; Padrini R; Ieiri I; Otsubo K; Kashima T; Kimura S; Kijima S; Echizen H
    Pharmacogenet Genomics; 2006 Feb; 16(2):101-10. PubMed ID: 16424822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population diversity and the performance of warfarin dosing algorithms.
    Suarez-Kurtz G
    Br J Clin Pharmacol; 2011 Sep; 72(3):451-3. PubMed ID: 21575037
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
    Gage BF; Eby C; Johnson JA; Deych E; Rieder MJ; Ridker PM; Milligan PE; Grice G; Lenzini P; Rettie AE; Aquilante CL; Grosso L; Marsh S; Langaee T; Farnett LE; Voora D; Veenstra DL; Glynn RJ; Barrett A; McLeod HL
    Clin Pharmacol Ther; 2008 Sep; 84(3):326-31. PubMed ID: 18305455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
    Horne BD; Lenzini PA; Wadelius M; Jorgensen AL; Kimmel SE; Ridker PM; Eriksson N; Anderson JL; Pirmohamed M; Limdi NA; Pendleton RC; McMillin GA; Burmester JK; Kurnik D; Stein CM; Caldwell MD; Eby CS; Rane A; Lindh JD; Shin JG; Kim HS; Angchaisuksiri P; Glynn RJ; Kronquist KE; Carlquist JF; Grice GR; Barrack RL; Li J; Gage BF
    Thromb Haemost; 2012 Feb; 107(2):232-40. PubMed ID: 22186998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of genetic, clinical, and INR data to refine warfarin dosing.
    Lenzini P; Wadelius M; Kimmel S; Anderson JL; Jorgensen AL; Pirmohamed M; Caldwell MD; Limdi N; Burmester JK; Dowd MB; Angchaisuksiri P; Bass AR; Chen J; Eriksson N; Rane A; Lindh JD; Carlquist JF; Horne BD; Grice G; Milligan PE; Eby C; Shin J; Kim H; Kurnik D; Stein CM; McMillin G; Pendleton RC; Berg RL; Deloukas P; Gage BF
    Clin Pharmacol Ther; 2010 May; 87(5):572-8. PubMed ID: 20375999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.
    Duconge J; Ramos AS; Claudio-Campos K; Rivera-Miranda G; Bermúdez-Bosch L; Renta JY; Cadilla CL; Cruz I; Feliu JF; Vergara C; Ruaño G
    PLoS One; 2016; 11(1):e0145480. PubMed ID: 26745506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model.
    Rodríguez-Fernández K; Reynaldo-Fernández G; Reyes-González S; de Las Barreras C; Rodríguez-Vera L; Vlaar C; Monbaliu JM; Stelzer T; Duconge J; Mangas-Sanjuan V
    Biomed Pharmacother; 2024 Jan; 170():115977. PubMed ID: 38056237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
    Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
    J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.
    M Hidjo MM; Chikwambi Z; Ngwende G; Matenga JA; Masimirembwa C
    Pharmacogenomics; 2023 Jul; 24(10):529-538. PubMed ID: 37435666
    [No Abstract]   [Full Text] [Related]  

  • 13. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.
    Crawford DC; Ritchie MD; Rieder MJ
    Pharmacogenomics; 2007 May; 8(5):487-96. PubMed ID: 17465713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.
    Salinger DH; Shen DD; Thummel K; Wittkowsky AK; Vicini P; Veenstra DL
    Pharmacogenet Genomics; 2009 Dec; 19(12):965-71. PubMed ID: 19881396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment: patient-specific factors predictive of warfarin dosage requirements.
    Lindh JD
    Ann Pharmacother; 2003 Mar; 37(3):454; author reply 454. PubMed ID: 12639185
    [No Abstract]   [Full Text] [Related]  

  • 16. VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.
    González Della Valle A; Khakharia S; Glueck CJ; Taveras N; Wang P; Fontaine RN; Salvati EA
    Clin Orthop Relat Res; 2009 Jul; 467(7):1773-80. PubMed ID: 19034590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of warfarin dosing in patients of African and European ancestry.
    Shendre A; Dillon C; Limdi NA
    Pharmacogenomics; 2018 Nov; 19(17):1357-1371. PubMed ID: 30345882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
    Cavallari LH; Perera M; Wadelius M; Deloukas P; Taube G; Patel SR; Aquino-Michaels K; Viana MA; Shapiro NL; Nutescu EA
    Pharmacogenet Genomics; 2012 Feb; 22(2):152-8. PubMed ID: 22158446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of warfarin in populations of African descent.
    Suarez-Kurtz G; Botton MR
    Br J Clin Pharmacol; 2013 Feb; 75(2):334-46. PubMed ID: 22676711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.
    Claudio-Campos K; Labastida A; Ramos A; Gaedigk A; Renta-Torres J; Padilla D; Rivera-Miranda G; Scott SA; Ruaño G; Cadilla CL; Duconge-Soler J
    Front Pharmacol; 2017; 8():347. PubMed ID: 28638342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.